Variant Gene Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo. 28388009

2018

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing. 28422737

2018

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE Lung cancer harboring epidermal growth factor receptor (EGFR) mutations and treated with EGFR tyrosine kinase inhibitors (TKIs) all eventually develop acquired resistance to the treatment, with half of the patients developing EGFR T790M resistance mutations. 28620690

2018

dbSNP: rs121434568
rs121434568
0.100 GeneticVariation BEFREE The discovery of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) has led to unprecedented clinical response in a subset of lung cancer patients carrying the sensitizing EGFR mutations (L858R or exon 19 deletion). 28774798

2017

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer. 28778263

2017

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403. 27506489

2017

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE Staurosporine scaffold-based rational discovery of the wild-type sparing reversible inhibitors of EGFR T790M gatekeeper mutant in lung cancer with analog-sensitive kinase technology. 27891677

2017

dbSNP: rs121434568
rs121434568
0.100 GeneticVariation BEFREE Ectopic expression of EGFR-L858R in lung cancer cells acted through activation of ERK signaling pathways to induce the expression of CXCR4. 26338423

2016

dbSNP: rs121434568
rs121434568
0.100 GeneticVariation BEFREE Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer. 26689995

2016

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells. 26052929

2016

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer. 26152920

2016

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE Loss of EPHA2 reduced the viability of erlotinib-resistant tumor cells harboring EGFR(T790M) mutations in vitro and inhibited tumor growth and progression in an inducible EGFR(L858R+T790M)-mutant lung cancer model in vivo. 26744526

2016

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study. 26577492

2016

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE We analyzed gene expression profiles of gefitinib-resistant PC9M2 cells that were derived from gefitinib-sensitive lung cancer PC9 cells and do not have known resistance mechanisms including EGFR mutation T790M. 26268703

2016

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. 25074459

2016

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer. 26400668

2016

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE The secondary epidermal growth factor receptor (EGFR) T790M mutation is the most prominent mechanism that confers resistance to first- or second-generation EGFR tyrosine kinase inhibitors (TKIs) in lung cancer treatment. 26752745

2016

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE Although this class of mutant-selective EGFR inhibitors is effective clinically in lung cancer patients harboring EGFR(T790M), prior preclinical studies demonstrate that acquired resistance can occur through genomic alterations that activate ERK1/2 signaling. 26036643

2016

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE Our findings contrast with the observations made in lung cancer patients where the EGFR-T790M-mutation is classified as a typical "second mutation"causing resistance to TKI-therapy during ongoing anticancer therapy. 26267891

2016

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. 24893891

2016

dbSNP: rs16969968
rs16969968
0.100 GeneticVariation BEFREE Accordingly, rs588765-rs16969968 may be a genetic marker to lung cancer risk, even among never-smokers. 26282330

2016

dbSNP: rs11540654
rs11540654
0.100 GeneticVariation BEFREE We conclude that not Pro47Ser SNP but Arg72Pro SNP is involved in susceptibility to developing lung cancer, at least in Bangladeshi population. 25034526

2015

dbSNP: rs121434568
rs121434568
0.100 GeneticVariation BEFREE Mechanistically, SPRY2 and RECK expressions were decreased by nickel-induced miR-21 via activation of the EGFR/NF-κB signaling pathway, which promoted invasiveness in lung cancer cells, and particularly in the cells with EGFR L858R expression vector transfection. 26026961

2015

dbSNP: rs121434568
rs121434568
0.100 GeneticVariation BEFREE Next, we examined the role of RhoB in lung cancer progression in transgenic mice that express inducible EGFR(L858R) crossed with Rhob null mice. 25320360

2015

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. 24736066

2015